Day One Biopharmaceuticals develops targeted therapies for pediatric patients with relapsed or refractory low-grade glioma, utilizing precision medicine approaches to enhance treatment efficacy. The company addresses the critical need for effective cancer treatments in children, aiming to improve survival rates and quality of life for young patients.
Funding
$175M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pediatric low-grade gliomas (pLGG) often relapse or become refractory to standard treatments, presenting a significant challenge in pediatric oncology. There is a need for more effective and targeted therapies to improve outcomes for these young patients.
Solution
Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric patients with relapsed or refractory pLGG. The company utilizes precision medicine approaches to identify and develop treatments that specifically target the unique characteristics of each patient's tumor. By focusing on targeted therapies, Day One aims to improve treatment efficacy and reduce the toxic side effects associated with traditional chemotherapy. Their FDA-approved medicine represents a significant advancement in the treatment of pLGG, offering hope for improved survival rates and quality of life for young patients.
Target Audience
The primary target audience is pediatric patients with relapsed or refractory low-grade glioma and the healthcare professionals who treat them.
Features
- Development of targeted therapies for pediatric cancer
- Precision medicine approach to tailor treatments to individual patients
- Focus on relapsed or refractory low-grade glioma
- FDA-approved medicine for pLGG